The Methylation-Specific Multiplex Ligation-Dependent Probe Amplification or MS-MLPA assays, involving numerous oligonucleotide probes complimentary to the FMR1 target sequence that spans a methylation-sensitive restriction endonuclease site, is also available for the diagnosis of FXS in males [121,122]. This evidence concerns the gene FMR1 and fragile X syndrome.